Viking Therapeutics VKTX Debt-to-equity

Debt-to-equity at other companies

Eli LillyLLY

1.6×-0.6×

PfizerPFE

0.7×0.0×

AmgenAMGN

4.9×-2.7×

Gyre Therapeutics, Inc.GYRE

0×0.0×

Madrigal Pharmaceuticals, Inc.MDGL

0.7×+0.5×

VAN

Vivani MedicalVANI

1×-0.7×

FAQ

What is Viking Therapeutics's debt-to-equity?

Viking Therapeutics (VKTX) reported debt-to-equity of 0× in Q4 2025.

How has Viking Therapeutics's debt-to-equity changed year-over-year?

Viking Therapeutics's debt-to-equity decreased by 84.6% year-over-year, from 0× to 0×.

What is the long-term trend for Viking Therapeutics's debt-to-equity?

Over 5 years (2020 to 2025), Viking Therapeutics's debt-to-equity has grown at a -33.2% compound annual growth rate (CAGR), from 0× to 0×.

What does debt-to-equity mean?

Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.